Screening services for pre-clinical development of neuro-pharmaceuticals and safety pharmacology

Functional screening procedures with cell cultures of neuronal networks

NeuroProof GmbH offers screening services which analyse and clarify the complex effect of substances on the function of the brain and the whole central nervous system.

The effect of potential medications on the CNS and possible neuro-toxic effects can be predicted early by means of these results. Thus it is possible to considerably accelerate the pre-clinical development of CNS drugs and to cut down on costs.

Only few enterprises throughout the world are able to cultivate primary neuron/glia-cocultures on MEA-neuro-chips and are currently offering it. Through this technology the specific nervous tissue taken from foetal mice can be kept alive for days and weeks. MEA-neuro-chips record the electronic patterns of action potentials of single neurons in the complex network which can be interpreted afterwards. Proprietary procedures of pattern recognition are applied for data analysis. Thus, the effect of CNS drugs can be examined directly which was not previously possible.

NeuroProof GmbH contributes significantly to the development of new neuro-pharmaceuticals in cooperation with its partners. For example, the company management participates in a project, supported by the EU, which aims to develop a novel analgesic for tumour patients.